

Message from the CEO, Dr. Randolph Kerschbaumer

As summer draws to a close, we at OncoOne are preparing for upcoming major industry conferences, continuing our fundraising efforts with potential partners and interested investors, and celebrating our recent corporate milestones. We would like to take this opportunity to provide an update on our progress over the last three months and how we intend to continue building value through the end of the year. We have continued sharing our preclinical data at several important scientific and business conferences this quarter and importantly, added three world-renowned MIF and macrophage experts to our Scientific Advisory Board. We thank you for your interest in our recent accomplishments and look forward to reconnecting in the near future!

Third Quarter 2022 Highlights

1. Earlier this month we announced the addition of 3 world-renowned MIF and macrophage biology experts: **Dr. Seamas Donnelly, Dr. Jennifer Guerriero, and Dr. Robert Mitchell** to our **Scientific Advisory Board**. Each SAB member provides a wealth of knowledge in the fields of oncology and immunology which will further complement the existing SAB as it supports the clinical readiness of our two next generation monoclonal antibody oxMIF assets. The newly expanded SAB recently concluded their first meeting with the board on September 20, 2022.



2. **Founder's Fall Tour:** We officially kicked off a tour of requested invitations featuring our founders. First up was our **Chief Technology Officer, Alexander Schinagl**, and his appearance at the **13th World Multispecifics Summit** in Boston on September 20-22. His presentation focused on our proprietary **PreTarg-it[®]** platform and its ability to utilize bispecific antibodies, designed for optimal penetration and tumor retention for an enhanced payload delivery. The tour will continue next month with our **CEO, Dr. Randolph Kerschbaumer** at the Macrophages-directed Therapies Summit, October 4-6, and **Dr. Michael Thiele, our Chief Scientific Officer** at the 10th Immuno-Oncology Summit, October 12-14, both held in Boston.



3. The OncoOne team has been working diligently throughout the summer to share the potential of our oxMIF targeting therapeutics and our deep understanding of MIF and its function as the critical driver of innate and adaptive immunity in oncology and immunology. Our **Chief Business Officer, Brent Meadows** held several 1:1 meetings

with leading investors and potential collaborators from big pharma at both the **BIO-Taiwan** in July and recently at the **ESMO Congress** in early September.

4. In August, **Dr. Christine Landlinger** presented preclinical data highlighting the potential of our lead candidate, ON203, a novel optimized oxMIF-specific monoclonal antibody designed to treat solid tumors at the **World Conference on Lung Cancer** hosted by our hometown of Vienna, Austria.

Upcoming Events: 4Q Connection Opportunities

- **CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON)**, September 28-October 1, in New York City (Poster, *ON203: A new anti-oxMIF antibody exerts antitumorigenic activity and modulates the tumor microenvironment in patient-derived tumoroids*)
- **4th Macrophage-directed Therapies Summit**, October 4-6, in Boston: **Chief Executive Officer, Dr. Randolph Kerschbaumer** has been invited to present an oral presentation entitled "*Targeting the Oxidized Macrophage Migration Inhibitory Factor (oxMIF) in Inflammation and its Link to Oncology*"
- **10th Immuno-Oncology Summit**, October 12-14, in Boston: **Chief Scientific Officer, Michael Thiele**, has been invited to present "*Modulation of the Tumor Microenvironment in 3D-Tumoroids Derived from Patients with Colorectal Cancer by Targeting the Oxidized Macrophage Migration Inhibitory Factor*"
- **Bio-Europe**, October 24-26, investment and partnering meetings in Leipzig, Germany
- **34th EORTC-NCI-AACR Symposium** on molecular targets and cancer therapeutics, October 26-28, in Barcelona (Poster, *ON203: A new antibody targeting the oxidized form of macrophage migration inhibitory factor demonstrates antitumorigenic activity in preclinical models*)
- **SITC 37th Annual Meeting & Pre-conference Programs**, November 8-12, in Boston, MA (Poster, "*ON203: A new antibody targeting the oxidized form of macrophage migration inhibitory factor (oxMIF) exerts antitumorigenic activity and modulates the tumor microenvironment*")
- **American College of Rheumatology Convergence**, November 10-14, in Philadelphia, PA (Poster, "*Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF) – a Novel Treatment Approach for Rheumatoid Arthritis*")

Please Stay in Touch! Follow us on [LinkedIn](#) and [Twitter @OncoOne](#)

OncoOne's founders **discovered** and **named** the **oxidized isoform of MIF** and are developing optimized monoclonal antibody-based therapies to **treat solid tumors and inflammation** as both single-agents or in combination with standard of care regimens.

OncoOne is currently holding discussions for **Series B financing** which will advance ON203 and ON104 towards Phase I clinical evaluation. We are also engaged in discussing partnering opportunities and collaborations including securing a strategic pharmaceutical partner to accelerate development.

Contact us: email Brent Meadows, CBO of OncoOne at brent.meadows@oncoone.com

Feel free to share this newsletter within your network. Thank you for reading!

Follow us on LinkedIn:

